International guidelines have recommended testing for the conventional mutations, EGFR, B-Raf, ALK and ROS1(Kerr et al., 2021), in advanced NSCLC with KRAS only being included in June 2021 (NCCN NSCLC guidelines). This evidence concerns the gene KRAS and non-small cell lung carcinoma.